Chilean President Boric Meets with SINOVAC Chairman and CEO Weidong Yin

2023-12-12

On December 12, 2023, Chilean President Gabriel Boric met with a delegation led by Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC, at the Presidential Palace La Moneda in Chile. Both sides have reached a consensus on local vaccine production and collaborative research and development of health products.

President Boric firstly mentioned about his recent successful visit to China. He emphasized that during his meeting with Chinese President Xi Jinping, both leaders jointly affirmed the need to further deepen cooperation in the health care among the numerous collaborations between China and Chile. He also stated that the Chilean government has established strategic goals for the development of vaccine research and industrialization in Chile.

Yin Weidong responded, "Mr. President’s visit to China was indeed very successful. Your charisma attracted many Chinese people and won praise. The purpose of our SINOVAC delegation's special visit to Chile is to better implement the consensus reached by the top leaders of both countries. We are exploring how to accelerate collaborative projects in vaccine research and industrialization between China and Chile." Developing vaccine's research and development and localization projects in Chile is the company's long-term strategy, and SINOVAC will firmly approach this goal which is highly consistent with the strategic direction of the Chilean government.

Yin Weidong stated that both sides have set up a special working group Studying Chile's successful anti-epidemic experience during the COVID-19 epidemic. It aims to maximize Chile's research strengths in bio-pharmaceutics and leverage SINOVAC's expertise in vaccine research and localization.

The goal is to face the pandemic challenge more efficiently, to enhance vaccine's accessibility and affordability, and to contribute to the health and well-being of the people in Chile and other countries in South America.

Chilean Minister of Economy Mr. Nicolás Grau, Minister of Science Mrs. Aisén Etcheverry, Undersecretary of Public Health Mrs. Andrea Albagli, Chairman of SINOVAC Quality Committee and Head of Latin America Region Mr. Weining Meng, and Ms. Barbara Orellana, Director of Regulatory Affairs SINOVAC Chile, also presented during the meeting.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC’s vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world’s first inactivated SARS vaccine (with Phase I clinical trials completed), China’s first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world’s first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world’s most widely used inactivated COVID-19 vaccine.Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.